共 131 条
[91]
Johannesson M., Jonsson B., Kjekshus J., Olsson A.G., Pedersen T.R., Wedel H., Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease, N Engl J Med, 336, 5, pp. 332-336, (1997)
[92]
Maclaine G.D., Patel H., A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels, Int J Clin Pract, 55, 4, pp. 243-249, (2001)
[93]
Muls E., Van Ganse E., Closon M.C., Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: Comparison between Belgium and the United States of a projected risk model, Atherosclerosis, 137, SUPPL., (1998)
[94]
Palmer S.J., Brady A.J., Ratcliffe A.E., The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS, Int J Clin Pract, 57, 9, pp. 792-800, (2003)
[95]
Pharoah P.D., Hollingworth W., Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population, BMJ, 312, 7044, pp. 1443-1448, (1996)
[96]
Pickin D.M., McCabe C.J., Ramsay L.E., Payne N., Haq I.U., Yeo W.W., Jackson P.R., Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug, Heart, 82, 3, pp. 325-332, (1999)
[97]
Prosser L.A., Stinnett A.A., Goldman P.A., Williams L.W., Hunink M.G., Goldman L., Weinstein M.C., Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics, Ann Intern Med, 132, 10, pp. 769-779, (2000)
[98]
Russell M.W., Huse D.M., Miller J.D., Kraemer D.F., Hartz S.C., Cost effectiveness of HMG-CoA reductase inhibition in Canada, Can J Clin Pharmacol, 8, 1, pp. 9-16, (2001)
[99]
Scuffham P.A., Chaplin S., An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK, Pharmacoeconomics, 22, 8, pp. 525-535, (2004)
[100]
Tsevat J., Kuntz K.M., Orav E.J., Weinstein M.C., Sacks F.M., Goldman L., Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels, Am Heart J, 141, 5, pp. 727-734, (2001)